2023.11.02 Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
2023.10.10 I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
2023.08.08 I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023